Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 3/2022

18.01.2022 | Original Article

Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019–2020)

verfasst von: Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Cecilia G. Carvalhaes, Mariana Castanheira

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study is to evaluate the activities of aztreonam-avibactam and comparator agents against Enterobacterales isolates from European medical centres as well as the occurrence of carbapenemases (CPEs). A total of 11,655 Enterobacterales isolates were collected consecutively in 2019–2020 from 38 medical centres located in Western Europe (W-EU; n = 8,784; 25 centres in 10 countries) and the Eastern European and Mediterranean region (E-EU; n = 2,871; 13 centres in 10 countries). Isolates were susceptibility tested by broth microdilution methods in a monitoring laboratory. The antimicrobial susceptibility and frequency of key resistance phenotypes were assessed and stratified by geographic region and infection type. Isolates that showed resistance to carbapenems (CRE) and/or elevated MICs (> 8 mg/L) for aztreonam-avibactam were screened for β-lactamase-encoding genes by whole-genome sequencing. Aztreonam-avibactam inhibited 99.9% of Enterobacterales at ≤ 8 mg/L (MIC50/90, ≤ 0.03/0.12 mg/L) and retained potent activity against CRE (MIC50/90, 0.25/0.5 mg/L), multidrug-resistant isolates (MDR; MIC50/90, 0.12/0.5 mg/L), and extensively drug-resistant (XDR) isolates (MIC50/90, 0.25/0.5 mg/L). Susceptibility to comparator agents was consistently lower among isolates from E-EU compared to W-EU for all infection types evaluated. CRE rates varied from 0.6% (urinary tract infection [UTI]) to 2.3% (bloodstream infection) in W-EU, and from 6.1% (UTI) to 17.0% (pneumonia) in E-EU. A CPE-encoding gene was identified in 360 of 424 (84.9%) CRE isolates, and the most common CPEs were blaKPC (36.3% of CRE), blaOXA-48 type (27.1% of CRE), and the MBLs (25.7% of CRE). All CPE producers were inhibited at an aztreonam-avibactam concentration of ≤ 8 mg/L. Aztreonam-avibactam demonstrated potent activity across the evaluated geographic regions and infection types.
Literatur
1.
Zurück zum Zitat Cornely OA, Cisneros JM, Torre-Cisneros J, Rodriguez-Hernandez MJ, Tallon-Aguilar L, Calbo E, Horcajada JP, Queckenberg C, Zettelmeyer U, Arenz D, Rosso-Fernandez CM, Jimenez-Jorge S, Turner G, Raber S, ÒBrien S, Luckey A, Group C-CcRS (2020) Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother 75(3):618–627CrossRef Cornely OA, Cisneros JM, Torre-Cisneros J, Rodriguez-Hernandez MJ, Tallon-Aguilar L, Calbo E, Horcajada JP, Queckenberg C, Zettelmeyer U, Arenz D, Rosso-Fernandez CM, Jimenez-Jorge S, Turner G, Raber S, ÒBrien S, Luckey A, Group C-CcRS (2020) Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother 75(3):618–627CrossRef
2.
Zurück zum Zitat Brogden RN, Heel RC (1986) Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 31(2):96–130CrossRef Brogden RN, Heel RC (1986) Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 31(2):96–130CrossRef
3.
Zurück zum Zitat Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF (2018) Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 66(8):1290–1297CrossRef Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF (2018) Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 66(8):1290–1297CrossRef
4.
Zurück zum Zitat Bush K, Bradford PA (2020) Epidemiology of beta-lactamase-producing pathogens. Clin Microbiol Rev 33(2):e00047CrossRef Bush K, Bradford PA (2020) Epidemiology of beta-lactamase-producing pathogens. Clin Microbiol Rev 33(2):e00047CrossRef
5.
Zurück zum Zitat Castanheira M, Deshpande LM, Mendes RE, Canton R, Sader HS, Jones RN (2019) Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infect Dis 6(Suppl 1):S23–S33CrossRef Castanheira M, Deshpande LM, Mendes RE, Canton R, Sader HS, Jones RN (2019) Variations in the occurrence of resistance phenotypes and carbapenemase genes among Enterobacteriaceae isolates in 20 years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infect Dis 6(Suppl 1):S23–S33CrossRef
6.
Zurück zum Zitat Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796CrossRef Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796CrossRef
7.
Zurück zum Zitat Pitout JDD, Peirano G, Kock MM, Strydom KA, Matsumura Y (2019) The global ascendency of OXA-48-type carbapenemases. Clin Microbiol Rev 33(1):e00102CrossRef Pitout JDD, Peirano G, Kock MM, Strydom KA, Matsumura Y (2019) The global ascendency of OXA-48-type carbapenemases. Clin Microbiol Rev 33(1):e00102CrossRef
8.
Zurück zum Zitat Boyd SE, Livermore DM, Hooper DC, Hope WW (2020) Metallo-beta-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother 64(10):e00397CrossRef Boyd SE, Livermore DM, Hooper DC, Hope WW (2020) Metallo-beta-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother 64(10):e00397CrossRef
9.
Zurück zum Zitat Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z (2019) NDM metallo-beta-lactamases and their bacterial producers in health care settings. Clin Microbiol Rev 32(2):e00115CrossRef Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z (2019) NDM metallo-beta-lactamases and their bacterial producers in health care settings. Clin Microbiol Rev 32(2):e00115CrossRef
10.
Zurück zum Zitat Fuhrmeister AS, Jones RN, Sader HS, Rhomberg PR, Mendes RE, Flamm RK, Le J, Denys G, Castanheira M, Deshpande LM, Canton R, Gales AC, Seifert H, Gur D, Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Cormican M, Streit JM, Huband MD, Tsakris A, Woosley LN, Cattoir V, Turnidge JD (2019) Global surveillance of antimicrobial resistance: 20 years of experience with the SENTRY Program. Open Forum Infect Dis 6(Supplement 1):S1–S102CrossRef Fuhrmeister AS, Jones RN, Sader HS, Rhomberg PR, Mendes RE, Flamm RK, Le J, Denys G, Castanheira M, Deshpande LM, Canton R, Gales AC, Seifert H, Gur D, Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Cormican M, Streit JM, Huband MD, Tsakris A, Woosley LN, Cattoir V, Turnidge JD (2019) Global surveillance of antimicrobial resistance: 20 years of experience with the SENTRY Program. Open Forum Infect Dis 6(Supplement 1):S1–S102CrossRef
11.
Zurück zum Zitat Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281CrossRef Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281CrossRef
12.
Zurück zum Zitat CLSI (2012) M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition. Clinical and Laboratory Standards Institute, Wayne, PA CLSI (2012) M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition. Clinical and Laboratory Standards Institute, Wayne, PA
13.
Zurück zum Zitat Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O’Donnell JP, Bradford PA, Eakin AE (2015) Pharmacokinetics/pharmacodynamics of a beta-lactam and beta-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother 70(9):2618–2626CrossRef Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O’Donnell JP, Bradford PA, Eakin AE (2015) Pharmacokinetics/pharmacodynamics of a beta-lactam and beta-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother 70(9):2618–2626CrossRef
14.
Zurück zum Zitat EUCAST (2021) Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, January 2021. European Committee on Antimicrobial Susceptibility Testing EUCAST (2021) Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, January 2021. European Committee on Antimicrobial Susceptibility Testing
15.
Zurück zum Zitat Mendes RE, Jones RN, Woosley LN, Cattoir V, Castanheira M (2019) Application of next-generation sequencing for characterization of surveillance and clinical trial isolates: analysis of the distribution of beta-lactamase resistance genes and lineage background in the United States. Open Forum Infect Dis 6(Suppl 1):S69–S78CrossRef Mendes RE, Jones RN, Woosley LN, Cattoir V, Castanheira M (2019) Application of next-generation sequencing for characterization of surveillance and clinical trial isolates: analysis of the distribution of beta-lactamase resistance genes and lineage background in the United States. Open Forum Infect Dis 6(Suppl 1):S69–S78CrossRef
16.
Zurück zum Zitat Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS, Castanheira M (2021) Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother 76(11):2833–2838CrossRef Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS, Castanheira M (2021) Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother 76(11):2833–2838CrossRef
17.
Zurück zum Zitat Sonnevend A, Ghazawi A, Darwish D, Barathan G, Hashmey R, Ashraf T, Rizvi TA, Pal T (2020) In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Int J Infect Dis 99:253–259CrossRef Sonnevend A, Ghazawi A, Darwish D, Barathan G, Hashmey R, Ashraf T, Rizvi TA, Pal T (2020) In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Int J Infect Dis 99:253–259CrossRef
18.
Zurück zum Zitat Alm RA, Johnstone MR, Lahiri SD (2015) Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother 70(5):1420–1428CrossRef Alm RA, Johnstone MR, Lahiri SD (2015) Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother 70(5):1420–1428CrossRef
19.
Zurück zum Zitat Estabrook M, Kazmierczak KM, Wise M, Arhin FF, Stone GG, Sahm DF (2021) Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017. J Glob Antimicrob Resist 24:316–320CrossRef Estabrook M, Kazmierczak KM, Wise M, Arhin FF, Stone GG, Sahm DF (2021) Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017. J Glob Antimicrob Resist 24:316–320CrossRef
20.
Zurück zum Zitat Sadek M, Ruppe E, Habib A, Zahra R, Poirel L, Nordmann P (2021) International circulation of aztreonam/avibactam-resistant NDM-5-producing Escherichia coli isolates: successful epidemic clones. J Glob Antimicrob Resist 27:326–328CrossRef Sadek M, Ruppe E, Habib A, Zahra R, Poirel L, Nordmann P (2021) International circulation of aztreonam/avibactam-resistant NDM-5-producing Escherichia coli isolates: successful epidemic clones. J Glob Antimicrob Resist 27:326–328CrossRef
21.
Zurück zum Zitat Sadek M, Juhas M, Poirel L, Nordmann P (2020) Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-beta-lactamase-producing Escherichia coli isolates. Antimicrob Agents Chemother 64(12):e01659CrossRef Sadek M, Juhas M, Poirel L, Nordmann P (2020) Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-beta-lactamase-producing Escherichia coli isolates. Antimicrob Agents Chemother 64(12):e01659CrossRef
22.
Zurück zum Zitat Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS (2021) Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Int J Antimicrob Agents 58(5):106439CrossRef Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS (2021) Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Int J Antimicrob Agents 58(5):106439CrossRef
23.
Zurück zum Zitat WHO (2017) Central Asian and Eastern European surveillance of antimicrobial resistance. World Health Organization, Copenhagen, Denmark WHO (2017) Central Asian and Eastern European surveillance of antimicrobial resistance. World Health Organization, Copenhagen, Denmark
24.
Zurück zum Zitat ECDC (2019) Surveillance of antimicrobial resistance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). European Centre for Disease Prevention and Control, Stockholm, Sweden ECDC (2019) Surveillance of antimicrobial resistance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). European Centre for Disease Prevention and Control, Stockholm, Sweden
25.
Zurück zum Zitat Fursova NK, Astashkin EI, Knyazeva AI, Kartsev NN, Leonova ES, Ershova ON, Alexandrova IA, Kurdyumova NV, Sazikina SY, Volozhantsev NV, Svetoch EA, Dyatlov IA (2015) The spread of bla OXA-48 and bla OXA-244 carbapenemase genes among Klebsiella pneumoniae, Proteus mirabilis and Enterobacter spp. isolated in Moscow. Russia. Ann Clin Microbiol Antimicrob 14:46CrossRef Fursova NK, Astashkin EI, Knyazeva AI, Kartsev NN, Leonova ES, Ershova ON, Alexandrova IA, Kurdyumova NV, Sazikina SY, Volozhantsev NV, Svetoch EA, Dyatlov IA (2015) The spread of bla OXA-48 and bla OXA-244 carbapenemase genes among Klebsiella pneumoniae, Proteus mirabilis and Enterobacter spp. isolated in Moscow. Russia. Ann Clin Microbiol Antimicrob 14:46CrossRef
26.
Zurück zum Zitat Protonotariou E, Meletis G, Chatzopoulou F, Malousi A, Chatzidimitriou D, Skoura L (2019) Emergence of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases in Greece. J Glob Antimicrob Resist 19:81–82CrossRef Protonotariou E, Meletis G, Chatzopoulou F, Malousi A, Chatzidimitriou D, Skoura L (2019) Emergence of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases in Greece. J Glob Antimicrob Resist 19:81–82CrossRef
27.
Zurück zum Zitat Sader HS, Carvalhaes CG, Duncan LR, Flamm RK, Shortridge D (2020) Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18. J Antimicrob Chemother 75(10):2907–2913CrossRef Sader HS, Carvalhaes CG, Duncan LR, Flamm RK, Shortridge D (2020) Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012–18. J Antimicrob Chemother 75(10):2907–2913CrossRef
28.
Zurück zum Zitat Suzuk Yildiz S, Simsek H, Bakkaloglu Z, Numanoglu Cevik Y, Hekimoglu CH, Kilic S, Alp Mese E, Calisma UKS, G, (2021) The epidemiology of carbapenemases in Escherichia coli and Klebsiella pneumoniae isolated in 2019 in Turkey. Mikrobiyol Bul 55(1):1–16CrossRef Suzuk Yildiz S, Simsek H, Bakkaloglu Z, Numanoglu Cevik Y, Hekimoglu CH, Kilic S, Alp Mese E, Calisma UKS, G, (2021) The epidemiology of carbapenemases in Escherichia coli and Klebsiella pneumoniae isolated in 2019 in Turkey. Mikrobiyol Bul 55(1):1–16CrossRef
29.
Zurück zum Zitat Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS, Pollock D, See I, Soe MM, Walters MS, Dudeck MA (2020) Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol 41(1):1–18CrossRef Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS, Pollock D, See I, Soe MM, Walters MS, Dudeck MA (2020) Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol 41(1):1–18CrossRef
30.
Zurück zum Zitat Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2021) Infectious Diseases Society of America guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 72(7):e169–e183CrossRef Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2021) Infectious Diseases Society of America guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 72(7):e169–e183CrossRef
Metadaten
Titel
Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019–2020)
verfasst von
Helio S. Sader
Rodrigo E. Mendes
S. J. Ryan Arends
Cecilia G. Carvalhaes
Mariana Castanheira
Publikationsdatum
18.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 3/2022
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-022-04400-z

Weitere Artikel der Ausgabe 3/2022

European Journal of Clinical Microbiology & Infectious Diseases 3/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.